DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that new data from its ongoing oncology programs will be featured in two poster presentations at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22–26 at the Hynes Convention Center in Boston, Massachusetts.
The presentations will highlight updated findings from early-stage studies of Aprea’s investigational WEE1 inhibitor, APR-1051, and its ATR inhibitor, ATRN-119. Both compounds are designed to target key pathways in DNA damage response and repair, offering potential treatment options for patients with advanced cancers harboring specific genetic alterations.
The first poster, “Early safety and efficacy of APR-1051, a novel WEE1 inhibitor, in patients with cancer-associated gene alterations: Updated data from ACESOT-1051 phase 1 trial,” will be presented by Philippe Pultar, M.D., with lead authorship by Anthony Tolcher, M.D., FRCPC. The second poster, “Updated data from ABOYA-119: A phase 1/2a trial of ATRN-119, a novel macrocyclic ATR inhibitor, in patients with advanced solid tumors harboring DNA damage,” will be presented by Oren Gilad, Ph.D., with Amit Mahipal, M.D., as lead author. Both presentations are scheduled for Friday, October 24, from 12:30 p.m. to 4:00 p.m. Eastern Time during Poster Session B in Exhibit Hall D.
Copies of both posters will be made available on Aprea’s corporate website under the Investor Resources section following the presentations.
Based in Doylestown, Pennsylvania, Aprea Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies focused on DNA damage response pathways to address unmet needs in oncology.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.